Mini‐Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI)
I Arevalo‐Rodriguez, N Smailagic… - Cochrane database …, 2015 - cochranelibrary.com
Background Dementia is a progressive global cognitive impairment syndrome. In 2010,
more than 35 million people worldwide were estimated to be living with dementia. Some …
more than 35 million people worldwide were estimated to be living with dementia. Some …
Mini‐Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI)
I Arevalo-Rodriguez, N Smailagic… - Cochrane Database …, 2021 - cochranelibrary.com
Background Dementia is a progressive global cognitive impairment syndrome. In 2010,
more than 35 million people worldwide were estimated to be living with dementia. Some …
more than 35 million people worldwide were estimated to be living with dementia. Some …
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
C Ritchie, N Smailagic, AH Noel‐Storr… - Cochrane Database …, 2014 - cochranelibrary.com
Background According to the latest revised National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders …
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders …
Fluid biomarkers in dementia diagnosis
SE Schindler - CONTINUUM: Lifelong Learning in Neurology, 2022 - journals.lww.com
PURPOSE OF REVIEW This article discusses how fluid biomarkers can augment the routine
dementia evaluation and improve diagnostic accuracy. The tests that are currently available …
dementia evaluation and improve diagnostic accuracy. The tests that are currently available …
Assessment of plasma and cerebrospinal fluid biomarkers in different stages of Alzheimer's disease and frontotemporal dementia
L Álvarez-Sánchez, C Peña-Bautista… - International Journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) is the primary type of dementia, followed by frontotemporal lobar
degeneration (FTLD). They share some clinical characteristics, mainly at the early stages …
degeneration (FTLD). They share some clinical characteristics, mainly at the early stages …
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
G Martínez, RWM Vernooij, PF Padilla… - Cochrane Database …, 2017 - cochranelibrary.com
Background 18 F‐florbetapir uptake by brain tissue measured by positron emission
tomography (PET) is accepted by regulatory agencies like the Food and Drug Administration …
tomography (PET) is accepted by regulatory agencies like the Food and Drug Administration …
[HTML][HTML] Advances in peripheral blood biomarkers of patients with Alzheimer's disease: Moving closer to personalized therapies
G Ferretti, S Serafini, A Angiolillo, P Monterosso… - Biomedicine & …, 2023 - Elsevier
Recently, measurable peripheral biomarkers in the plasma of patients with Alzheimer's
disease (AD) have gained considerable clinical interest. Several studies have identified one …
disease (AD) have gained considerable clinical interest. Several studies have identified one …
A review of dementia, focusing on the distinct roles of viral protein corona and MMP9 in dementia: Potential pharmacotherapeutic priorities
Dementia, in particular, is a defining feature of Alzheimer's and Parkinson's diseases.
Because of the combination of motor and cognitive impairments, Parkinson's disease …
Because of the combination of motor and cognitive impairments, Parkinson's disease …
Biological Diagnosis of Alzheimer's Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?
B Souchet, A Michaïl, B Billoir, J Braudeau - International Journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) was first characterized by Dr. Alois Alzheimer in 1906 by studying
a demented patient and discovering cerebral amyloid plaques and neurofibrillary tangles …
a demented patient and discovering cerebral amyloid plaques and neurofibrillary tangles …
Guideline summary: assessment, diagnosis, care and support for people with dementia and their carers [Scottish Intercollegiate Guidelines Network SIGN Guideline …
Abstract The Scottish Intercollegiate Guidelines Network (SIGN) have recently published
their guideline SIGN168 on 'Assessment, Diagnosis, Care, and Support for People with …
their guideline SIGN168 on 'Assessment, Diagnosis, Care, and Support for People with …